SCHEMBL16020358

SCHEMBL16020358

COC(=O)c1cc(S(=O)(=O)Nc2cc(C)cnc2OC)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ GAA P10253 2/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ MAPK1 P28482 2/20 0.49
▸ CCR9 P51686 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ TSHR P16473 1/20 0.47
▸ CCR2 P41597 6/20 0.47
▸ CYP3A4 P08684 4/20 0.47
▸ CCR4 P51679 3/20 0.47
▸ CYP2C9 P11712 3/20 0.47
▸ CYP2C19 P33261 3/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CCR5 P51681 1/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16020329 0.91 CCR2 (0.54) LMNAALDH1A1GAACCR9CCR2
SCHEMBL24140017 0.86 LMNA (0.51) LMNAALDH1A1GAAL3MBTL1MAPK1
SCHEMBL16017575 0.86 LMNA (0.51) LMNAALDH1A1GAAL3MBTL1MAPK1
SCHEMBL13976112 0.81 SLC40A1 (0.58) LMNAALDH1A1TSHRCYP2C9MEN1
SCHEMBL16020343 0.81 TP53 (0.52) LMNAALDH1A1MAPK1TSHRCCR2
SCHEMBL16020325 0.80 ALDH1A1 (0.51) LMNAALDH1A1GAACCR2CYP3A4
SCHEMBL16020338 0.80 KMT2A (0.53) LMNAALDH1A1GAACCR2CYP3A4
SCHEMBL13975944 0.78 CCR2 (0.52) LMNAALDH1A1GAACCR2CYP3A4
SCHEMBL16017569 0.78 CCR2 (0.52) LMNAALDH1A1GAACCR9CCR2
SCHEMBL24140018 0.77 KMT2A (0.52) LMNAALDH1A1GAACCR2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9808466-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 2017-11-07 — — US disclosed
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2016-10-13 — — US disclosed
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 LMNA 1273/4885ALDH1A1 4625/4885GAA 1870/4885
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 LMNA 1273/4885ALDH1A1 4625/4885GAA 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback